DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

SHINE secures rights to new method for Lutetium-177 production Generate Lu-177 at greater speed and scale

FDA gives green light to new United Imaging PET/MR scanner The uPMR 790 HD TOF performs total-body scans within 20 minutes

FDA reminder for properly eluting rubidium 82 generators prompted by 'recent incidents' Using incorrect solutions puts patients at risk

Generating higher quality PET images 100x faster at MSK 'No one has done PET imaging in this way before'

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

Amyloid PET scans help with Alzheimer's clinical management

by Thomas Dworetzky , Contributing Reporter
Getting brain scans for Alzheimer's hallmark amyloid plaque “significantly influenced clinical management of patients with mild cognitive impairment and dementia,” a nation-wide study has found.

"We are impressed by the magnitude of these results, which make it clear that amyloid PET imaging can have a major impact on how we diagnose and care for patients with Alzheimer's disease and other forms of cognitive decline," study lead author and principal investigator Dr. Gil Rabinovici, professor of Neurology at the UCSF Memory and Aging Center and member of the UCSF Weill Institute for Neurosciences, said in a statement.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



The multicenter study of over 11,000 Medicare recipients, published in JAMA, showed that in 60 percent of cases clinicians armed with PET scan results changed both the use of medication and counseling for mild cognitive impairment and dementia. That was double the impact predicted by researchers. The effort involved scientists from the Alzheimer's Association, UC San Francisco, Brown University School of Public Health, Virginia Commonwealth University School of Public Health, Washington University School of Medicine in St. Louis, UC Davis School of Medicine, and the Kaiser Permanente Division of Research, and was managed by the American College of Radiology.

The researchers concluded that the use of amyloid PET was associated with clinical management changes within 90 days, they reported in the journal.

"These results present highly credible, large-scale evidence that amyloid PET imaging can be a powerful tool to improve the accuracy of Alzheimer's diagnosis and lead to better medical management, especially in difficult-to-diagnose cases," suggested Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and a coauthor of the study. "It is important that amyloid PET imaging be more broadly accessible to those who need it."

While there is no cure for the devastating cognitive decline, catching it early permits patients, families and their healthcare providers to tackle such crucial issues as safety and care-planning for the future – and if no plaque is found on PET scan, it can also lead to identifying other, potentially reversible, causes of memory loss.

The tracers used are FDA approved, but at present Medicare and health insurance plans do not cover amyloid PET imaging to aid in dementia diagnosis, according to researchers.

The results come from the Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) study that enlisted the aid of almost 1,000 dementia specialists at 595 sites in the U.S.
  Pages: 1 - 2 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED